Quantum BioPharma Ltd. (NASDAQ: QNTM) Developing Patented, First-in-Class MS Treatment That Offers Different Approach
Quantum BioPharma announced that its lead drug candidate Lucid-MS is preparing to enter Phase 2 clinical trials, targeting the myelin sheath to treat multiple sclerosis. The company retains a 19.84% ownership stake in Unbuzzd Wellness Inc., a spinout entity, and is entitled to a 7% royalty on sales until total payments reach $250 million, after which the rate drops to 3% in perpetuity.
Key figures
- Drug Name
- Lucid-MS
- Phase Of Trial
- Phase 2
- Unbuzzd royalty cap
- $250 million
- Ms patients worldwide
- 2.9 million
- Unbuzzd ownership percent
- 19.84%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.